Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for...
CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber...
Revenue Growth of +9.8% at Actual Exchange Rates (AER); +4.5% at Constant Exchange Rate (CER) Driven by Strong Momentum of Growth & Launch...
LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin...
— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June...
Six Late-Stage Programs with Peak Revenue Potential of $10B - $20B1 Poised to Deliver Sustainable Growth Expected Phase 3 Data Readouts in 2025...
Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval...
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone...
Umsatzwachstum von +13,4 % zu aktuellen Wechselkursen (AER); +5,0 % zu konstanten Wechselkursen (CER) Getrieben durch die kontinuierliche...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지